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Objective: The recent appreciation that stenting has improved the short- and long-
term outcomes of patients treated with coronary angioplasty has made it imperative
to reconsider the comparison between surgery and percutaneous interventions in
patients with multivessel disease.
Methods: One thousand two hundred five patients were randomly assigned to
undergo bypass surgery or angioplasty with stent implantation when there was
consensus between the cardiac surgeon and interventional cardiologist as to equiv-
alent treatability. The primary clinical end point was freedom from major adverse
cardiac and cerebrovascular events at 1 year. Major adverse cardiac and cerebro-
vascular events at 2 years constituted a secondary end point.
Results: At 2 years, 89.6% of the surgical group and 89.2% of the stent group were
free from death, stroke, and myocardial infarction (log-rank test P  .65). Among
patients who survived without stroke or myocardial infarction, 19.7% in the stent
group underwent a second revascularization, as compared with 4.8% in the surgical
group (P  .001). At 2 years, 84.8% of the surgical group and 69.5% of the stent
group were event-free survivors (log-rank test P  .001), and 87.2% in the surgical
cohort and 79.6 % in the stent group were angina-free survivors (P  .001). In the
diabetes subgroup, 82.3% of the surgical group and 56.3% of the stent group were
free from any events after 2 years (log-rank test P  .001).
Conclusion: The difference in outcome between surgery and stenting observed at 1
year in patients with multivessel disease remained essentially unchanged at 2 years.
Stenting was associated with a greater need for repeat revascularization. In view of
the relatively greater difference in outcome in patients with diabetes, surgery clearly
seems to be the preferable form of treatment for these patients.
Stenting has had a significant impact on coronary revascularization.The volume of stented angioplasty has exceeded all expectations andis more than the volume of cardiac surgery.1 European statisticsestimate the annual need for percutaneous coronary interventions at739 per million inhabitants and coronary artery bypass grafting at 436per million inhabitants.2 Approximately 60% of these patients have
multivessel disease and potentially could be treated with either bypass surgery or
balloon angioplasty.3 Despite the publication of a number of trials comparing bypass
surgery with angioplasty,4 the most appropriate treatment is still a matter of debate.
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These trials suggest that the results are similar in terms of
survival and myocardial infarctions but that patients who
undergo bypass surgery require fewer reinterventions.
The major concerns of surgeons are incompleteness of
revascularization and the high rate of repeat interventions
with angioplasty. When interpreting the results from these
earlier trials, however, it is important to realize that im-
provements in both surgical and percutaneous techniques
have occurred, calling into question the current validity of
these earlier conclusions. Thus although surgery may still be
seen as the most appropriate technique for multivessel dis-
ease when compared with conventional balloon angioplasty,
this may not be true when stent placement—the current
standard of practice5,6—is added to the angioplasty proce-
dure.
The specific aim of this study was to evaluate the clinical
outcomes of patients with multivessel coronary artery dis-
ease treated with stented angioplasty versus conventional
bypass surgery in a large, well-controlled, multicenter, mul-
tinational study. This report focuses in detail on outcomes of
the surgical cohort. There is also an overall comparison of
the outcomes in the surgical and stent groups at 2 years and
an analyis of the differences in the pattern of response in
patients with diabetes.
Methods
Study Design
The Arterial Revascularization Therapies Study (ARTS) was a
randomized trial that required a consensus of the surgeon and the
interventional cardiologist regarding equivalent treatability of the
patient by either technique. Informed consent was obtained from
each patient and the institutional review board approved the pro-
tocol. A detailed description of the protocol has been reported
elsewhere.7
Selection of Patients
Patients with angina or ischemia but no previous bypass surgery or
angioplasty were selected after agreement between surgeons and
cardiologists, randomly assigned after written informed consent
through a central telephone service, and treated with either surgery
or stented angioplasty. Sixty percent of patients in the surgical arm
and 57% in the stent arm had stable angina (Canadian Cardiovas-
cular Society class 1, 2, 3, or 4).8 Unstable angina pectoris (Braun-
wald class IB, IC, IIB, IIC, IIIB, or IIIC)9 was present in 35% of
the surgical group versus 37% of the stent group, and silent
ischemia was present in 5% of the surgical group and 6% of the
stent group (Table 1). Patients were eligible for coronary revascu-
larization if they had at least two de novo lesions (located in
different vessels and in different territories) potentially amenable
to bypass surgery or stent implantation. Patients with left main
stem stenosis were excluded.
Concomitant risk factor modification was an important aspect
of treatment for all patients in the ARTS trial. Smokers were
counseled and assisted with smoking cessation. Patients with hy-
pertension were required to have their blood pressure lowered to
less than 140/90 mm Hg. Patients with diabetes were required to be
treated with diet, exercise, oral agents, and insulin as clinically
indicated. Pharmacologic treatment was instituted for patients with
total cholesterol level greater than 5.5 mmol/L, according to the
most recent European guidelines.10
Exclusion criteria included a left ventricular ejection fraction
less than 30%, overt congestive heart failure, a history of previous
cerebrovascular accident, transmural myocardial infarction within
the previous week, severe hepatic or renal disease, diseased sa-
phenous veins, and the need for concomitant major surgery (eg,
valve surgery or resection of aortic or left ventricular aneurysm,
carotid endarterectomy, abdominal aortic aneurysm surgery). Fi-
nally, patients with intolerance or contraindication to aspirin or
ticlopidine and those with neutropenia or thrombocytopenia were
also excluded.
General Management Considerations and Operator
Certification
Surgery and cardiac interventions were performed at 67 sites. The
institutions involved in the ARTS trial had to perform at least 400
coronary bypass procedures per year in which the thoracic artery
was used in 80% of the cases.11 The standard procedure for
coronary bypass entailed extracorporeal circulation and cardiac
arrest. The internal thoracic artery had to be used for revascular-
ization of the left anterior descending coronary artery or the
diagonal branches during extracorporeal circulation. The use of
other arterial conduit material was discouraged. The remaining
vessels could be bypassed by use of the greater saphenous vein in
whatever configuration the surgeon deemed appropriate. Anes-
thetic techniques and the type of cardioplegic solution were not
standardized.
A minimum of 500 angioplasty cases per center and a mini-
mum of 100 procedures per year per operator were required for
sites to qualify as participants in the ARTS trial. Angiographic
criteria for inclusion in the trial have been previously been pub-
lished elsewhere.7
End Points
The objective of this study was to compare bypass surgery with
stented angioplasty with the Cordis Palmaz-Schatz Crown or
CrossFlex stent (Cordis Corporation, Miami Lakes, Fla) in patients
with multivessel coronary disease. The primary end point was
defined as the absence of any of the following major adverse
cardiac and cerebrovascular events within 12 months after random
assignment: death, cerebrovascular event, documented nonfatal
myocardial infarction, or repeated revascularization by percutane-
ous intervention or bypass surgery.7,12 In the primary comparison
of the two treatment strategies, all deaths (cardiac and noncardiac
causes) were reported. Cerebrovascular events were classified into
three major categories: stroke, transient ischemic attack, and re-
versible ischemic neurologic deficit.
After random assignment, all myocardial infarctions were
counted as events, whether they occurred spontaneously or in
association with coronary artery bypass grafting surgery or angio-
plasty procedures. Myocardial infarctions were confirmed only
after the relevant electrocardiograms were analyzed by the elec-
trocardiographic core laboratory and adjudicated by the clinical
events committee. Every subsequent revascularization procedure
was recorded, including the reasons for the procedure.
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Secondary objectives of the study were to compare both strat-
egies at 2 years with respect to the following: anginal status;
medication use; the combined end point of death, myocardial
infarction and stroke; and the itemized outcomes of death, myo-
cardial infarction, stroke, or revascularization procedure. Events
were counted from the time of random assignment, whereas the
clinical status was assessed at predetermined times of 1 month, 6
months, 12 months, and 24 months after the procedure.
One patient was unavailable for follow up, 3 were alive but had
withdrawn their consent from further participation in the trial, and
2 patients were never treated with either modality.
Statistical Analysis
The required sample size (2 600 patients) was based on rejection
of the null hypothesis that at 1 year the frequency of major adverse
cardiac and cerebrovascular events in favor of bypass surgery
(event-free survival) would not exceed 7%. The actual sample size
achieved a power of 92% with the assumption of a 2-sided type I
error level () of .05.
Continuous variables were expressed as mean  SD and com-
pared with the unpaired Student t test. The Fisher exact test was
used for categoric variables. Wilcoxon scores were used for cate-
goric variables with an ordinal scale. Discrete variables were
expressed as counts and percentages and were compared in terms
of relative risks (for surgery vs stenting) with 95% confidence
intervals calculated by the formula of Greenland and Robins.13 All
statistical tests were 2-tailed. Event-free survivals were estimated
according to the Kaplan-Meier method, and differences were as-
sessed with the log-rank test.
Results
Patient Characteristics and Study Flow Chart
Between April 1997 and June 1998, a total of 1205 patients
were randomly assigned to undergo coronary artery bypass
grafting surgery (605 patients) or angioplasty with stent
implantation (600 patients) at 67 participating centers. Ta-
ble 1 shows their baseline demographic and angiographic
characteristics. As indicated in Table 2, 5 patients (1 as-
signed to undergo stented angioplasty and 4 assigned to
undergo surgery) did not undergo coronary revasculariza-
tion and instead continuted to receive pharmacologic treat-
ment. The average time elapsed between random assign-
TABLE 1. Baseline characteristics of the patients included in the intent-to-treat-analysis
Stented
angioplasty
(n  600)
Coronary artery
bypass grafting
(n  605)
Male sex 77% 76%
Age (y, mean  SD) 61 10 (30-83) 61 9 (32-82)
Body mass index (kg/m2, mean  SD) 27.2 3.7 27.4 3.7
Previous conditions
Myocardial infarction (Q-wave and non-Q-wave) 44% 42%
Diabetes mellitus 19% 16%
Hypertension 45% 45%
Hypercholesterolemia 58% 58%
Family history 39% 42%
Peripheral vascular disease 6% 5%
Chronic obstructive pulmonary disease 5% 5%
Current smoker 28% 26%
Stable angina* 57% 60%
Unstable angina† 37% 35%
Silent ischemia 6% 5%
Ejection fraction (%) 61% 12% 60% 13%
Segments DS 50% 2.83 1.02 2.80 1.04
No. of vessels diseased
One 1.5% 0.3%
Two 68.1% 66.6%
Three 30.4% 33.1%
Vessel territory‡
Right coronary artery 71.2% 72.4%
Left anterior descending artery 89.9% 90.5%
Left circumflex artery 71.2% 72.4%
Left main stem artery§ 0.2% 0.2%
Bifurcation or side branch involved‡ 34% 31%
Total occlusion‡ 3% 5%
*According to the classification system of the Canadian Cardiovascular Society.
†According to reference 16.
‡Assessed by an independent angiographic core laboratory.
§Protocol violation.
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ment and treatment was 27  39 days (range 0-362 days)
for the surgical group and 11  16 days (range 0-173 days)
for the stent group. Three patients assigned to undergo
surgery died while on the waiting list. Six patients allocated
to the stent arm crossed over to the surgical treatment arm,
whereas 19 patients assigned to surgery were treated with
stent implantation. During the initial hospital stay, 14 pa-
tients initially assigned to undergo stenting underwent sur-
gical revascularization, 3 urgently and 11 electively, after a
complicated or unsatisfactory percutaneous treatment. Sim-
ilarly, 2 patients who had undergone surgery had further
angioplasty during the same hospital stay. Thus 579 patients
in the surgical group (95.9%) and 593 patients in the stent
group (98.8%) were treated according to the assigned treat-
ment.
Assessment of Revascularization (Figure 1)
There were 579 patients actually operated on; 2.8  1.1
lesions per patient were present, and 2.7  1.1 distal anas-
tomoses were performed with 2.5  0.7 conduits. At least
one arterial conduit was used in 93% of the cases, and the
left anterior descending artery was revascularized with an
arterial conduit in 95%; 1.8% of the patients received a
single bypass, 51.6% received a double bypass, 33.6%
received a triple bypass, 6.9% received a quadruple bypass,
and 0.5% received a quintuple bypass. The mean operative
time for surgery was 248  76 minutes, the mean bypass
time was 75  35 minutes, and the mean crossclamp time
was 45  27 minutes. Cardiac arrest was achieved with
crystalloid cardioplegia in 325 cases and blood cardioplegia
in 191. In the remainder, a combination of techniques was
used with additional crossclamping and topical hypothermia
in 284 patients. To manage cardiac failure after the opera-
tion, prolonged extracorporeal circulation was necessary in
1% of the cases and intra-aortic balloon pumping was
necessary in 2.4%. A left ventricular assist device was
necessary in 1%.
In the first 24 hours after intervention, abnormal creatine
kinase MB levels were observed in 61% of the surgical
group and 31% of the stent group. Eight patients died in the
hospital between 1 and 18 days after the operation. The
causes of death were excessive bleeding (1 patient), ven-
tricular fibrillation (n  2), mesenteric infarction (n  2),
cardiogenic shock (n  2), and myocardial infarction (n 
1). The overall operative mortality was 1.3%. By compari-
son, the in-hospital mortality rate in the stented angioplasty
group was 1% (n  6). A total of 571 patients were weaned
off the bypass machine, extubated, and discharged from
hospital. The lengths of stay were 11.3  9.1 days in the
surgical group and 3.4  4.8 days in the stent group.
Outcomes at 30 Days after Random Assignment
At 30 days after random assignment there were a total of 11
deaths, including the 3 deaths of patients on the waiting list.
A further 6 patients had a cerebrovascular event (1.0%), and
18 had a myocardial infarction (3.0%). Reintervention was
necessary in 1 case (0.2%) by means of bypass surgery and
in 1 case (0.2%)by additional angioplasty. The events in the
stented angioplasty group were similar: 9 patients died
(1.5%, including the 6 in-hospital deaths), 4 patients (0.7%)
had a cerebrovascular accident, and 19 patients (3.0%) had
a myocardial infarction.
Outcomes at 1 Year
The outcomes at 1 year have previously been discussed in
detail elsewhere.12 The primary end-point criterion was met
by 157 of 600 patients (26.2%) assigned to undergo stented
angioplasty and 74 of 605 patients (12.2%) assigned to
TABLE 2. Study flow chart
Stented
angioplasty
(n  600)
Coronary artery
bypass grafting
(n  605)
Patients randomly assigned 600 605
Treated according to random assignment 593 (98.8%) 579 (95.9%)
Medical treatment only 1 4
Time on waiting list (d, mean  SD) 11 16 27 39
Deaths on waiting list 0 3
Cross-over from stent to coronary artery bypass grafting* 6 —
Cross-over from coronary artery bypass grafting to stent† — 19
(0-173) (0-362)
Unavailable for follow-up at 2 years‡ 2 4
*Three patients withdrew consent, 2 patients had significant left main disease, and in 1 case inappropriate patient selection occurred.
†Eight patients withdrew consent, in 8 cases the inclusion criteria were not met, in 1 case there was a miscommunication between the investigator and
the study coordinator about the random assignment, 1 patient had a Q-wave myocardial infarction while on the waiting list, and 1 patient had unstable
angina develop while on the waiting list and was treated with stented angioplasty.
‡One patient was unavailable for follow-up, 3 were alive but had withdrawn their consent from further participation in the trial, and 2 patients were never
treated with either modality.
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undergo bypass surgery (relative risk 2.14; 95% confidence
interval 1.66-2.75). There was no significant difference in
freedoms from death, stroke, or myocardial infarction be-
tween the stent and surgical groups (90.7% vs 91.2%, re-
spectively, relative risk 1.07, 95% confidence interval 0.75-
1.52). Of the remaining patients, however, 16.8% in the
stent group and 3.5% in the surgical group underwent re-
peated revascularization, an absolute difference of 13.3%.
Outcomes at 2 Years
Events per patient and ranking of clinical events at 2-year
follow-up are shown in Table 3. The primary clinical end
point (major adverse cardiac and cerebrovascular events)
was reached by 92 (15.2%) of the 605 patients assigned to
undergo bypass surgery, compared with 183 (30.5%) of the
600 patients assigned to undergo stented angioplasty (rela-
tive risk 0.39, 95% confidence interval 0.29-0.53). Free-
doms from death, stroke, and myocardial infarction were
similar in the surgical and the stented angioplasty groups
(89.6% vs 89.2%, respectively, relative risk 0.92, 95%
confidence interval 0.62-1.35). The difference in clinical
outcomes between the study groups at 2 years was almost
entirely due to the need for more repeated revascularizations
in the stent group.
Among patients free from death, stroke, and myocardial
infarction, the need for additional revascularization was
14.9% higher after percutaneous treatment than after sur-
gery. This difference in clinical outcome for both treated
groups is reflected in the Kaplan-Meier estimates of event-
free survival and freedom from death, stroke, and myocar-
dial infarction (Figure 2). The improved 2-year outcome in
the surgical group is also partly reflected in the differences
in anginal status and antianginal medication use between the
two groups (Table 4). At 2-year follow-up, 87.2% of the
surgical group were symptom free, compared with 79.7% of
the stent group (P  .001).
Diabetes
A total of 208 patients in this study (17.3%) had diabetes
(3.2% with type 1; Table 3). The primary clinical end point
had been reached at 2 years by 17 of the 96 patients with
diabetes assigned to undergo bypass surgery (17.7%), ver-
sus 49 of the 112 assigned to undergo stented angioplasty
(43.8%, relative risk 2.47; 95% confidence interval 1.53-
3.99). The incidences of death, stroke, and myocardial in-
farction were similar (14.6% in the surgical group vs 16.1%
in the stent group, relative risk 1.10, 95% confidence inter-
val 0.58-2.10). However, the reintervention rate was mark-
edly lower among the patients with diabetes who were
treated with surgery than among those who were treated
with stented angioplasty (5.2% vs 35.7%, relative risk 6.86,
95% confidence interval 2.82-16.68). This absolute differ-
ence in the need for reintervention of 30.5% was also
markedly higher than the difference of 19.1% observed for
the total group and the absolute difference of 13.2% for the
patients without diabetes.
Discussion
Coronary artery bypass surgery is a well-established and
well-documented technique. However, angioplasty with
stent implantation has had a significant impact on the refer-
rals of patients for surgery during the past few years. Al-
though the role of angioplasty in patients with single-vessel
disease is well established, it has generally been assumed
that bypass surgery is the procedure of choice for patients
with multivessel disease. Arguments for angioplasty have
included that it is less invasive and that there are long
waiting lists for surgery. Surgeons have countered with
Figure 1. Percentages of vessels revascularized in surgical and stented angioplasty cohorts.
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concerns that angioplasty may provide incomplete revascu-
larization and have responded by creating off-pump and
minimally invasive surgical techniques. The surgical com-
munity has watched the advances in stented angioplasty
with great interest, because they have had a significant
impact on referrals for surgery, with a resulting dramatic
reduction or even elimination of surgical waiting lists. Sur-
geons naturally wonder whether this trend toward stented
angioplasty rather than surgery is justified by the available
scientific evidence.
The ARTS trial allows a direct comparison of two en-
tirely different approaches to coronary revascularization in
patients with multivessel coronary artery disease. This trial
showed no significant difference in the frequency of death,
stroke, and myocardial infarction between surgery and
stented angioplasty. It is important to emphasize that in the
early postoperative period the mortalities in the two arms
were very similar (0.7 % vs 1%).12 The most significant
difference in favor of surgery was related to the need for
repeated revascularization at 24 months (14.9% difference).
Compared with previous trials with balloon angioplasty
alone in a similar population,5 the need for urgent surgical
revascularization after failed or complicated balloon angio-
plasty had fallen from 4.6%5 to 0.5%. As noted previously,
TABLE 3. Frequencies of primary clinical end points at 2 years (730 days) in descending order of severity and total number
of events
RANKING* Patients with events†
Relative
risk
95% confidence
interval
Stented
angioplasty
Coronary artery
bypass grafting
Stented
angioplasty
Coronary artery
bypass grafting
All patients 600 605 600 605
Patients with diabetes 112 96 112 96
Death
All patients 16 (2.8%) 22 (3.6%) 17 (2.8%) 22 (3.6%) 0.78 0.42-1.45
Patients with diabetes 8 (7.1%) 3 (3.1%) 8 (7.1%) 3 (3.1%) 2.29 0.62-8.38
CVA‡
All patients 14 (2.3%) 16 (2.6%) 16 (1.7%) 13 (2.1%) 0.95 0.48-1.86
Patients with diabetes 3 (2.7%) 6 (6.3%) 4 (3.6%) 6 (6.3%) 0.57 0.17-1.97
Myocardial infarction
All patients 34 (5.7%) 25 (4.1%) 40 (6.7%) 31 (5.1%) 1.30 0.83-2.05
Patients with diabetes 7 (6.3%) 5 (5.2%) 10 (8.9%) 7 (7.3%) 1.22 0.49-3.09
Q-wave myocardial infarction
All patients 28 (4.7%) 21 (3.5%) 33 (5.5%) 26 (4.3%) 1.28 0.78-2.11
Patients with diabetes 6 (5.4%) 2 (2.1%) 8 (7.1%) 4 (4.2%) 1.71 0.53-5.52
Non-Q-wave myocardial infarction
All patients 6 (1.0%) 4 (0.7%) 7 (1.2%) 5 (0.8%) 1.41 0.45-4.42
Patients with diabetes 1 (0.9%) 3 (3.1%) 2 (1.8%) 3 (3.1%) 0.57 0.10-3.35
Reintervention
All patients 118 (19.7%) 29 (4.8%) 147 (24.5%) 33 (5.5%) 4.49 3.13-6.44
Patients with diabetes 31 (27.7%) 3 (3.1%) 40 (35.7%) 5 (5.2%) 6.86 2.82-16.68
Reoperative coronary artery bypass grafting
All patients 40 (6.7%) 5 (0.8%) 53 (8.8%) 7 (1.2%) 7.64 3.50-16.66
Patients with diabetes 11 (9.8%) 0 (0.0%) 14 (12.5%) 2 (2.1%) 6.00 1.40-25.74
Reinterventional percutaneous transluminal coronary angioplasty
All patients 78 (13.0%) 24 (4.0%) 107 (17.8%) 30 (5.0%) 3.60 2.44-5.31
Patients with diabetes 20 (17.9%) 3 (3.1%) 28 (25.0%) 4 (4.2%) 6.00 2.18-16.50
Event free§
All patients 417 (69.5%) 513 (84.8%)
Patients with diabetes 63 (56.3%) 79 (82.3%)
Any event
All patients 183 (30.5%) 92 (15.2%) 2.01 1.60-2.51
Patients with diabetes 49 (43.8%) 17 (17.7%) 2.47 1.53-3.99
In the stented angioplasty arm 1 patient had a myocardial infarction while on the waiting list, whereas in the coronary artery bypass grafting arm 3 patients
died while on the waiting list, 1 patient had a cerebrovascular accident, and 4 patients had myocardial infarctions.
*Frequency of primary clinical end points in descending order of severity.
†If a patient required repeat angioplasty and later coronary artery bypass grafting, the total count at 365 days would reflect both events, not just the first
that occurred.
‡In the stent group 5 cases were thrombotic, 1 was hemorrhagic, and others were unknown. In the surgical group 7 were thrombotic, 1 was hemorrhagic,
and others were unknown.
§Wilcoxon rank-sum test (P  .0001).
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the difference in clinical outcome at 1 year between the
surgical and percutaneous approach has been reduced by
approximately 50% relative to other studies.5 This consid-
erable improvement in the percutaneous approach is due
largely to the increased safety and partial prevention of
restenosis provided by the stent.
In the ARTS trial the degree of revascularization
achieved in the group treated with multivessel stenting is
now comparable to that in the surgical cohort. In this trial
2.7 out of 2.8 stenotic lesions detected on the diagnostic
angiogram were successfully treated with stented angio-
plasty, whereas in the Coronary Angioplasty versus Bypass
Revascularisation Investigation trial14 only 2.1 out of 3.4
stenotic lesions were successfully treated, and in the Bypass
Angioplasty Revascularization Investigation trial15 only 1.9
out of 3.5 stenotic lesions were successfully treated. The
adequacy of revascularization with surgical techniques in
this study in the surgical cohort was very similar: 2.7 out of
2.8 lesions detected were treated with bypass grafts. The
aim of surgery is always to achieve complete revasculariza-
tion.
The ARTS trial was designed in April 1996 and initiated
in April 1997; patient recruitment was completed in June
1998. During this period the time that elapsed between
Figure 2. Two-year event-free survival curves of patients enrolled in ARTS trial and assigned to undergo stenting
(broken line) versus bypass surgery (solid line). A, Actuarial survival for stent group versus surgical group (P 
.75).
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random assignment and treatment was approximately three
times as long for the surgical cohort as for the stent cohort.
Eight major adverse cardiac events occurred in the surgical
group during the waiting period, versus 1 in the stent group.
There are reports that the waiting list for cardiac surgery is
in itself a considerable risk factor for these patients.16-18
Since 1997, the waiting-time for surgery has been markedly
reduced or even eliminated in many countries. It is also
worth noting that the in-hospital stay was more than three
times as long for patients undergoing surgery as for those
undergoing stented angioplasty. This difference has proba-
bly not changed substantially.
In the selection of centers for the trial, it was surprising
that many centers could not be included because they did
not routinely use the internal thoracic artery, not to mention
an all-arterial approach. The use of an internal thoracic graft
to the left anterior descending and saphenous vein grafts to
the remaining vessels that require treatment still appears to
be the standard of care, at least in Europe.19 Adoption of this
standard was necessary to ensure a basically similar ap-
proach to surgery in all 67 centers.
Evolving Technology
There have been new developments in coronary revascular-
ization, such as off-pump surgery, minimally invasive ap-
proaches, and new techniques in anesthesiology.20-23 Al-
Figure 2. Cont’d. B, Kaplan-Meier event-free survival curves for death, myocardial infarction, or cerebrovascular
events for stent group versus surgical group (P  .71).
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though these techniques may affect practice in the future,
they did not represent standard practice except at a few
centers of excellence.11,24-25 Thus the surgical data in this
trial reflected the standardized approach to bypass surgery
in 67 centers in 25 countries, not the standard of total
arterial arterialization that might potentially be achieved in
some centers of excellence.
However, the same caveats apply to the patients treated
with stented angioplasty. Percutaneous stent procedures
have also evolved substantially since 1997. Direct stenting
without balloon predilatation and intracoronary radiation
therapy26,27 for in-stent restenosis are now part of the car-
diologist’s armamentarium. It is also worth noting that 40%
of the 30-day events in the stent group were due to stent
thrombosis, which occurred in 1.1% of the stented lesions
but 3% of the patients. These events might have been
prevented by the use of a glycoprotein receptor antagonist28
or heparin-coated stents.5 Finally, drug-eluting stents may
Figure 2. Cont’d. C, Kaplan-Meier event-free survival curves for death, cerebrovascular events, myocardial
infarction, or any repeated revascularization stent group versus surgical group (P  .0001).
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markedly reduce restenosis and the need for repeated revas-
cularization.29 These therapies, although promising, also
cannot yet be considered “standard practice.”
Diabetes
This study corroborates the findings of the Bypass Angio-
plasty Revascularization Investigation trial with respect to
the adverse clinical impact of diabetes in patients undergo-
ing percutaneous coronary interventions. On the basis of
these data, it seems that bypass surgery is clearly the pre-
ferred approach for the treatment of patients with diabetes
who have multivessel disease. For patients without diabetes
the choice represents a series of trade-offs. There was no
difference at 2 years in terms of death, myocardial infarc-
tion, or cerebrovascular accident between surgery and
stented angioplasty. However, there was a substantially
greater need for repeated interventions in the stent group,
with the associated need for rehospitalization. On the other
hand, surgery was associated with a longer initial hospital
stay, a prolonged period of recovery, and greater costs.
These trade-offs should be presented to the patient, and the
best approach for each individual patient should be chosen
after careful consideration of all the facts.
Limitations of the Study
Because of strict inclusion and exclusion criteria, patients
treated in this study represent a small segment of patients
treated by the study surgeons. Surgeons often operate on
patients with more extensive disease than reported on in this
study, and most randomized trials recruit eligible patients
who represent only a small fraction of the population ame-
nable to surgical revascularization. In this trial a prospective
universe analysis showed that in any given week between
0% and 33% of patients with multivessel disease at the
participating institution were actually enrolled in the ARTS
trial. This wide range is attributable both to the restrictive
eligibility criteria for the study and to local logistic consid-
erations. In essence, these trials should be viewed as scien-
tific experience testing concepts, expanding our knowledge
of the field of revascularization and unraveling the need for
improvement.
We thank Dr Brian Firth for his careful review of the manu-
script and constructive comments.
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